48 Other results comments: No comment made on mode of delivery of NIPPV. Study sample sizes relatively small. Included studies appear of intermediate quality. No difference in mortality between CPAP and BiPAP. Significant reduction in need for IPPV for both CPAP and BIPAP. No significant difference in hospital stay between treatment groups. Weak evidence of an increase in new MI with Bi-level ventilation. EBM Comments: 1. Do the methods allow accurate testing of the hypothesis? Yes 2. Do the statistical tests correctly test the results to allow differentiation of statistically significant results? Yes 3. Are conclusions valid in light of the results? Yes 4. Did results get omitted, and why? Yes. Studies not randomised or inappropriate endpoints. Descriptive studies. 5. Did they suggest areas of further research? Yes. Role of PEEP/EPAP in relation to increased incidence of MI. Role of BiPAP in hypercapnic patients. 6. Did they make any recommendations based on the results and were they appropriate? Yes. That the British Thoracic Societies recommendations are appropriate: CPAP should be used in patients with cardiogenic pulmonary oedema who still have hypoxia despite the best medical The use of CPAP in cardiogenic pulmonary oedema significantly reduces mortality. Bi-level ventilation is associated with a non significant trend towards reduced mortality Level of Evidence: 1 + (meta-analysis with low risk of bias) Citation/s: John V. Peter, et al. Effect of noninvasive positive pressure ventilation ( NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Three-part Clinical Question: Patients: Patients with cardiogenic pulmonary oedema. Intervention: NIPPV (CPAP and Bi-level) Outcomes: Reduce mortality, need for IPPV, length of hospital stay and what are the associated failure rates plus incidence of new MI. Search Terms: Pulmonary oedema, heart failure, respiratory insufficiency, positive pressure ventilation, continuous positive airway pressure, non-invasive ventilation, non-invasive positive pressure ventilation, nasal ventilation and BIPAP The Review: Data Sources: Cochrane Library, Medline, Embase, Citation Index, hand search, non-English sources, Am. Coll. Of Physicians (ACP) J Club, DARE Study Selection: Randomised trials on acute cardiogenic pulmonary oedema. Comparing standard therapy (oxygen by facemask, diuretics, nitrates and other supportive care) with CPAP or Bi-level NIPPV. Only trials reporting hospital mortality or need for IPPV were included. Trials classified into 3 groups: (i) CPAP versus standard therapy, (ii) bi-level ventilation versus standard therapy and (iii) CPAP versus bi-level ventilation. Data Extraction: The studies were reviewed by two investigators, differences in opinion settled by consensus. They were tested for heterogeneity. The Evidence: Comparison Mortality RR (95% CI) p-value NNT CPAP vs standard therapy 0.59 (0.38-0.90) 0.015 10 Bi-level ventilation vs 0.63 (0.37-1.10) 0.11 NS standard therapy Bi-level ventilation 0.75 (0.40-1.43) 0.38 NS vs CPAP
Data Extraction: The studies were reviewed by two investigators, differences in opinion settled by consensus. They were tested for heterogeneity.
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